Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Aug;41(8):1797–1801. doi: 10.1128/aac.41.8.1797

Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp.

J E Sjøstrøm 1, T Kühler 1, H Larsson 1
PMCID: PMC164008  PMID: 9257764

Abstract

Proton pump inhibitors of the benzimidazole type exert a specific antibacterial activity against Helicobacter pylori in vitro. In the present study, the basis for this selectivity was investigated, and in particular, various factors affecting the in vitro antibacterial activity of sulfide analogs of benzimidazoles were studied. Upon preincubation of omeprazole for a period of up to 72 h in a buffer at pH 7, a product was formed that was bactericidal for H. pylori but had no effect on urease activity. Sulfide constitutes the main end product of degradation. The sulfide analog of omeprazole (H 168/22) exerted a bactericidal activity specifically against both resting (in buffer) and growing (in broth) Helicobacter spp., and time-kill in buffer at pH 5 was enhanced compared to that at pH 7. There was no or very low covalent binding of 3H-labeled H 168/22 to Helicobacter spp. or to other gram-negative and gram-positive bacteria. In the presence of fetal calf serum (FCS) under the same conditions, binding was only slightly lowered while the killing activity was markedly reduced, indicating a probably nonspecific interaction with proteins and/or protection of bacterial target(s) by FCS. Addition of H 168/22 (four times the minimum bactericidal concentration [MBC]) to exponentially growing H. pylori immediately stopped growth, and after an incubation period of 20 h viable counts were reduced by >7 log10. One-hour exposure of H. pylori to the drug followed by repeated washing retarded growth by about 2 h, indicating that the effect is reversible after short-term exposure. MICs and MBCs of various sulfide structures were lower than those obtained in broth after the addition of the corresponding sulfoxide. Thus, the MBC of the sulfide structure of omeprazole against 140 clinical isolates of H. pylori ranged from 8 to 32 microg/ml, compared to an MBC of omeprazole of 32 to 128 microg/ml. A similar potency was also recorded against other helicobacters. In conclusion, formation of sulfides of benzimidazoles in culture media is the reason for the selective antibacterial effect against H. pylori. The sulfides rapidly exerted a reversible antibacterial activity, which was specific against both resting and growing Helicobacter spp. without any covalent protein binding.

Full Text

The Full Text of this article is available as a PDF (223.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belli W. A., Fryklund J. Partial characterization and effect of omeprazole on ATPase activity in Helicobacter pylori by using permeabilized cells. Antimicrob Agents Chemother. 1995 Aug;39(8):1717–1720. doi: 10.1128/aac.39.8.1717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fellenius E., Berglindh T., Sachs G., Olbe L., Elander B., Sjöstrand S. E., Wallmark B. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase. Nature. 1981 Mar 12;290(5802):159–161. doi: 10.1038/290159a0. [DOI] [PubMed] [Google Scholar]
  3. Fryklund J., Gedda K., Wallmark B. Specific labelling of gastric H+,K+-ATPase by omeprazole. Biochem Pharmacol. 1988 Jul 1;37(13):2543–2549. doi: 10.1016/0006-2952(88)90244-4. [DOI] [PubMed] [Google Scholar]
  4. Ge Z., Hiratsuka K., Taylor D. E. Nucleotide sequence and mutational analysis indicate that two Helicobacter pylori genes encode a P-type ATPase and a cation-binding protein associated with copper transport. Mol Microbiol. 1995 Jan;15(1):97–106. doi: 10.1111/j.1365-2958.1995.tb02224.x. [DOI] [PubMed] [Google Scholar]
  5. Graham D. Y., de Boer W. A., Tytgat G. N. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol. 1996 Jun;91(6):1072–1076. [PubMed] [Google Scholar]
  6. Haque M., Hirai Y., Yokota K., Oguma K. Steryl glycosides: a characteristic feature of the Helicobacter spp.? J Bacteriol. 1995 Sep;177(18):5334–5337. doi: 10.1128/jb.177.18.5334-5337.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hebden R. A., Claybaugh J. R., Hashiro G. M. Comparative effects of Des Leu Angiotensin I and Angiotensin II on AVP secretion from the hypothalamoneurohypophysis and pituitary of the rat. Life Sci. 1992;51(3):195–202. doi: 10.1016/0024-3205(92)90075-z. [DOI] [PubMed] [Google Scholar]
  8. Hirai Y., Haque M., Yoshida T., Yokota K., Yasuda T., Oguma K. Unique cholesteryl glucosides in Helicobacter pylori: composition and structural analysis. J Bacteriol. 1995 Sep;177(18):5327–5333. doi: 10.1128/jb.177.18.5327-5333.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Iwahi T., Satoh H., Nakao M., Iwasaki T., Yamazaki T., Kubo K., Tamura T., Imada A. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991 Mar;35(3):490–496. doi: 10.1128/aac.35.3.490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kane A. V., Plaut A. G. Unique susceptibility of Helicobacter pylori to simethicone emulsifiers in alimentary therapeutic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):500–502. doi: 10.1128/aac.40.2.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kühler T. C., Fryklund J., Bergman N. A., Weilitz J., Lee A., Larsson H. Structure-activity relationship of omeprazole and analogues as Helicobacter pylori urease inhibitors. J Med Chem. 1995 Dec 8;38(25):4906–4916. doi: 10.1021/jm00025a008. [DOI] [PubMed] [Google Scholar]
  12. Lee A., Hazell S. L., O'Rourke J., Kouprach S. Isolation of a spiral-shaped bacterium from the cat stomach. Infect Immun. 1988 Nov;56(11):2843–2850. doi: 10.1128/iai.56.11.2843-2850.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mauch F., Bode G., Malfertheiner P. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol. 1993 Oct;88(10):1801–1802. [PubMed] [Google Scholar]
  14. Midolo P. D., Turnidge J. D., Lambert J. R., Bell J. M. Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro. Antimicrob Agents Chemother. 1996 Jun;40(6):1531–1533. doi: 10.1128/aac.40.6.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Moran A. P., Helander I. M., Kosunen T. U. Compositional analysis of Helicobacter pylori rough-form lipopolysaccharides. J Bacteriol. 1992 Feb;174(4):1370–1377. doi: 10.1128/jb.174.4.1370-1377.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nagata K., Satoh H., Iwahi T., Shimoyama T., Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother. 1993 Apr;37(4):769–774. doi: 10.1128/aac.37.4.769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nagata K., Takagi E., Tsuda M., Nakazawa T., Satoh H., Nakao M., Okamura H., Tamura T. Inhibitory action of lansoprazole and its analogs against Helicobacter pylori: inhibition of growth is not related to inhibition of urease. Antimicrob Agents Chemother. 1995 Feb;39(2):567–570. doi: 10.1128/aac.39.2.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Paster B. J., Lee A., Fox J. G., Dewhirst F. E., Tordoff L. A., Fraser G. J., O'Rourke J. L., Taylor N. S., Ferrero R. Phylogeny of Helicobacter felis sp. nov., Helicobacter mustelae, and related bacteria. Int J Syst Bacteriol. 1991 Jan;41(1):31–38. doi: 10.1099/00207713-41-1-31. [DOI] [PubMed] [Google Scholar]
  19. Sjöström J. E., Fryklund J., Kühler T., Larsson H. In vitro antibacterial activity of omeprazole and its selectivity for Helicobacter spp. are dependent on incubation conditions. Antimicrob Agents Chemother. 1996 Mar;40(3):621–626. doi: 10.1128/aac.40.3.621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sjöström J. E., Larsson H. Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant. J Med Microbiol. 1996 Jun;44(6):425–433. doi: 10.1099/00222615-44-6-425. [DOI] [PubMed] [Google Scholar]
  21. Suerbaum S., Leying H., Klemm K., Opferkuch W. Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 1991 Feb;10(2):92–93. doi: 10.1007/BF01964416. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES